Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 79 clinical-stage projects, 23 of which are in phase 3 or have been submitted to regulatory authorities for approval. Some of these are new molecular entities while others are existing products with potential new indications, or different formulations. All of them are made possible by people who volunteer to participate in a clinical trial.
Search for a specific a clinical-stage projects
Therapeutic Area
Immunology & Inflammation
Name
SAR441566
Phase
Description
Indication
Psoriasis
Psoriasis
Therapeutic Area
Immunology & Inflammation
Name
SAR443765
Phase
Description
Indication
Asthma
Asthma
Therapeutic Area
Immunology & Inflammation
Name
SAR444336
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
SAR444559
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
SAR445399
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
SAR445611
Phase
Description
Indication
Inflammatory indication
Inflammatory indication
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Asthma
Asthma
Therapeutic Area
Immunology & Inflammation
Name
amlitelimab
Phase
Description
Indication
Atopic Dermatitis
Atopic Dermatitis
Therapeutic Area
Immunology & Inflammation
Name
Dupixent®
Phase
Description
Indication
Ulcerative Colitis
Ulcerative Colitis
Therapeutic Area
Immunology & Inflammation
Name
eclitasertib
Phase
Description
Indication
Ulcerative Colitis
Ulcerative Colitis
Therapeutic Area
Immunology & Inflammation
Name
frexalimab
Phase
Description
Indication
Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Therapeutic Area
Immunology & Inflammation
Name
frexalimab
Phase
Description
Indication
Sjögren‘s Syndrome
Sjögren‘s Syndrome
Therapeutic Area
Immunology & Inflammation
Name
Kevzara®
Phase
Description
Indication
Systemic juvenile arthritis
Systemic juvenile arthritis
Therapeutic Area
Immunology & Inflammation
Name
Kevzara®
Phase
Description
Indication
Polyarticular juvenile idiopathic arthritis
Polyarticular juvenile idiopathic arthritis
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Indication
Chronic spontaneous urticaria
Chronic spontaneous urticaria
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Indication
Asthma
Asthma
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Indication
IgG4-related disease
IgG4-related disease
Therapeutic Area
Immunology & Inflammation
Name
SAR442970
Phase
Description
Indication
Hidradenitis Suppurativa
Hidradenitis Suppurativa
Therapeutic Area
Immunology & Inflammation
Name
SAR444656
Phase
Description
Indication
Hidradenitis Suppurativa
Hidradenitis Suppurativa
Therapeutic Area
Immunology & Inflammation
Name
SAR444656
Phase
Description
Indication
Atopic dermatitis
Atopic dermatitis
Therapeutic Area
Immunology & Inflammation
Name
SAR445088
Phase
Description
Indication
Antibody-mediated rejection
Antibody-mediated rejection
Therapeutic Area
Immunology & Inflammation
Name
Dupixent®
Phase
Description
Indication
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
Therapeutic Area
Immunology & Inflammation
Name
Dupixent®
Phase
Description
Indication
Bullous pemphigoid
Bullous pemphigoid
Therapeutic Area
Immunology & Inflammation
Name
Dupixent®
Phase
Description
Indication
Chronic pruritis of unknown origin
Chronic pruritis of unknown origin
Therapeutic Area
Immunology & Inflammation
Name
itepekimab
Phase
Description
Indication
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease
Therapeutic Area
Immunology & Inflammation
Name
TZIELD™
Phase
Description
Indication
Type 1 Diabetes
Type 1 Diabetes
Therapeutic Area
Immunology & Inflammation
Name
Dupixent®
Phase
Description
Indication
Chronic spontaneous urticaria
Chronic spontaneous urticaria
Therapeutic Area
Neurology
Name
SAR446159
Phase
Description
Indication
Parkinson's disease
Parkinson's disease
Therapeutic Area
Neurology
Name
frexalimab
Phase
Description
Indication
Multiple sclerosis
Multiple sclerosis
Therapeutic Area
Neurology
Name
SAR443820
Phase
Description
Indication
Multiple sclerosis
Multiple sclerosis
Therapeutic Area
Neurology
Name
SAR443820
Phase
Description
Indication
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Therapeutic Area
Neurology
Name
SAR445088
Phase
Description
Indication
Chronic inflammatory demyelinating polyneuropathy
Chronic inflammatory demyelinating polyneuropathy
Therapeutic Area
Neurology
Name
tolebrutinib
Phase
Description
Indication
Secondary Progressive MS
Secondary Progressive MS
Therapeutic Area
Neurology
Name
tolebrutinib
Phase
Description
Indication
Primary Progressive MS
Primary Progressive MS
Therapeutic Area
Neurology
Name
tolebrutinib
Phase
Description
Indication
Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Therapeutic Area
Oncology
Name
pegenzileukin
Phase
Description
Indication
Solid tumors (dose optimization)
Solid tumors (dose optimization)
Therapeutic Area
Oncology
Name
SAR442257
Phase
Description
Indication
Multiple myeloma / Non-Hodgkin lymphoma
Multiple myeloma / Non-Hodgkin lymphoma
Therapeutic Area
Oncology
Name
SAR443216
Phase
Description
Indication
Gastric cancer
Gastric cancer
Therapeutic Area
Oncology
Name
SAR443579
Phase
Description
Indication
Acute Myeloid Leukemia
Acute Myeloid Leukemia
Therapeutic Area
Oncology
Name
SAR444200
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR444881
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR445419
Phase
Description
Indication
Acute Myeloid Leukemia
Acute Myeloid Leukemia
Therapeutic Area
Oncology
Name
SAR445514
Phase
Description
Indication
Relapsed, Refractory Multiple Myeloma
Relapsed, Refractory Multiple Myeloma
Therapeutic Area
Oncology
Name
SAR445710
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR445877
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
SAR446309
Phase
Description
Indication
Solid tumors
Solid tumors
Therapeutic Area
Oncology
Name
Sarclisa®
Phase
Description
Indication
1-2L AML / acute lymphoblastic leukemia pediatrics
1-2L AML / acute lymphoblastic leukemia pediatrics
Therapeutic Area
Oncology
Name
Sarclisa®
Phase
Description
Indication
Relapsed, Refractory Multiple Myeloma
Relapsed, Refractory Multiple Myeloma
Therapeutic Area
Oncology
Name
tusamitamab ravtansine
Phase
Description
Indication
Gastric cancer
Gastric cancer
Therapeutic Area
Oncology
Name
tusamitamab ravtansine
Phase
Description
Indication
Exploratory solid tumors
Exploratory solid tumors
Therapeutic Area
Oncology
Name
tusamitamab ravtansine
Phase
Description
Indication
Non-small-cell lung cancer 2/3L
Non-small-cell lung cancer 2/3L
Therapeutic Area
Oncology
Name
tusamitamab ravtansine
Phase
Description
Indication
1L Non-small-cell lung cancer
1L Non-small-cell lung cancer
Therapeutic Area
Oncology
Name
Sarclisa®
Phase
Description
Indication
2/3L Relapsed, Refractory Multiple Myeloma
2/3L Relapsed, Refractory Multiple Myeloma
Therapeutic Area
Oncology
Name
Sarclisa®
Phase
Description
Indication
Smoldering multiple myeloma
Smoldering multiple myeloma
Therapeutic Area
Oncology
Name
Sarclisa®
Phase
Description
Indication
1L newly diagnosed multiple myeloma Te
1L newly diagnosed multiple myeloma Te
Therapeutic Area
Oncology
Name
Sarclisa®
Phase
Description
Indication
1L newly diagnosed multiple myeloma Ti
1L newly diagnosed multiple myeloma Ti
Therapeutic Area
Oncology
Name
tusamitamab ravtansine
Phase
Description
Indication
2/3L Non-small cell lung cancer
2/3L Non-small cell lung cancer
Therapeutic Area
Rare Blood Disorders
Name
rilzabrutinib
Phase
Description
Indication
Warm Autoimmune Hemolytic Anemia
Warm Autoimmune Hemolytic Anemia
Therapeutic Area
Rare Blood Disorders
Name
SAR445088
Phase
Description
Indication
Cold Agglutinin Disease
Cold Agglutinin Disease
Therapeutic Area
Rare Blood Disorders
Name
fitusiran
Phase
Description
Indication
Hemophilia A and B pediatric
Hemophilia A and B pediatric
Therapeutic Area
Rare Blood Disorders
Name
fitusiran
Phase
Description
Indication
Hemophilia A and B
Hemophilia A and B
Therapeutic Area
Rare Blood Disorders
Name
rilzabrutinib
Phase
Description
Indication
Immune Thrombocytopenia
Immune Thrombocytopenia
Therapeutic Area
Rare Diseases
Name
SAR439459
Phase
Description
Indication
Osteogenesis Imperfecta
Osteogenesis Imperfecta
Therapeutic Area
Rare Diseases
Name
SAR442501
Phase
Description
Indication
Achondroplasia
Achondroplasia
Therapeutic Area
Rare Diseases
Name
SAR443809
Phase
Description
Indication
Rare renal diseases
Rare renal diseases
Therapeutic Area
Rare Diseases
Name
SAR444836
Phase
Description
Indication
Phenylketonuria
Phenylketonuria
Therapeutic Area
Rare Diseases
Name
Nexviazyme®
Phase
Description
Indication
Pompe disease, infantile onset
Pompe disease, infantile onset
Therapeutic Area
Rare Diseases
Name
venglustat
Phase
Description
Indication
Fabry disease
Fabry disease
Therapeutic Area
Rare Diseases
Name
venglustat
Phase
Description
Indication
GM2 Gangliosidosis
GM2 Gangliosidosis
Therapeutic Area
Rare Diseases
Name
venglustat
Phase
Description
Indication
Gaucher disease type 3
Gaucher disease type 3
Therapeutic Area
Vaccines
Name
SP0256
Phase
Description
Indication
RSV older adults
RSV older adults
Therapeutic Area
Vaccines
Name
SP0273
Phase
Description
Indication
Influenza
Influenza
Therapeutic Area
Vaccines
Name
Fluzone® HD
Phase
Description
Indication
Pediatric Influenza
Pediatric Influenza
Therapeutic Area
Vaccines
Name
SP0125
Phase
Description
Indication
Respiratory syncytial virus (toddler)
Respiratory syncytial virus (toddler)
Therapeutic Area
Vaccines
Name
SP0202
Phase
Description
Indication
Pneumococcal infection
Pneumococcal infection
Therapeutic Area
Vaccines
Name
SP0218
Phase
Description
Indication
Yellow Fever
Yellow Fever
Therapeutic Area
Vaccines
Name
SP0230
Phase
Description
Indication
Meningitis B
Meningitis B
Therapeutic Area
Vaccines
Name
MenQuadfi™
Phase
Description
Indication
Meningitis, 6 weeks+ (USA / EU)
Meningitis, 6 weeks+ (USA / EU)
Therapeutic Area
Vaccines
Name
VRVg
Phase
Description
Indication
Rabies
Rabies
Program Updates
The following changes occurred in our R&D programs.
Updated on October 27, 2023
Therapeutic Area
Immunology & Inflammation
Name
SAR445399
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
SAR445611
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
eclitasertib
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
rilzabrutinib
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
SAR442970
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
SAR444656
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
SAR444656
Phase
Description
Additional Details
Therapeutic Area
Immunology & Inflammation
Name
TZIELD™
Phase
Description
Additional Details
Therapeutic Area
Oncology
Name
alomfilimab
Phase
Description
Additional Details
Therapeutic Area
Rare Diseases
Name
SAR444836
Phase
Description
Additional Details
Therapeutic Area
Vaccines
Name
Beyfortus®
Phase
Description
Additional Details